DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS Homozygous familial hypercholesterolemia affects 1 in 300,000 people and can cause cardiovascular disease in children under age 10. Cumulative lifetime LDL-C exposure, not single-point measurements, is the stronger ASCVD predictor, yet many pediatric patients go undiagnosed because they show no physical symptoms.
Clinical Considerations
- Lifetime cholesterol burden drives risk more than any single LDL-C value, making early detection and sustained treatment the primary clinical imperative.
- LDL-C thresholds for suspicion: above 160 mg/dL with family history of premature CVD; above 190 mg/dL without known history, per expert guidance.
- Universal pediatric screening is recommended between ages 9 and 11 and again between 17 and 21, with earlier fasting lipid panels (ages 2 to 8) indicated when family history includes premature cardiovascular disease or hypercholesterolemia.
- Statins initiated in childhood can shift management from reactive adult treatment to proactive prevention, substantially reducing long-term cardiovascular risk.
Practice Applications
- Obtain a detailed three-generation family history for all pediatric patients, prioritizing premature CVD and known hypercholesterolemia.
- Screen children with positive family history as early as age 2 using a fasting lipid panel rather than waiting for universal screening windows.
- Refer pediatric patients with LDL-C above threshold values for genetic testing to confirm inherited risk and guide treatment intensity.
- Initiate statin therapy early when HoFH is confirmed; do not defer treatment pending symptom development.
More in Pediatric Cardiology
